Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsDowngradesPrice TargetHot
Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.
Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.